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ABSTRACT
ANALYSIS OF p73 GENE IN HEPATOCELLULAR CARCINOMA
Necati Fındıklı
M.S. in Molecular Biology and Genetics 
Supervisor; Prof. Dr. Mehmet Óztürk
August 1998
Hepatocellular carcinoma (HCC) is the eighth most frequent cancer worldwide, 
iipidemiologically-studied risk factors include hepatitis B virus (greater than 80%), 
hepatitis C virus and aflatoxins. Molecular mechanisms of hepatocarcinogenesis are 
poorly understood. The only gene known to be consistently involved in these tumors is 
the p53 tumor suppressor gene. However, this gene was found to be mutated or 
ifiactivated in about 30% of HCC. There is a need to study additional genes in order to 
fully understand hepatocellular carcinogenesis. p73 has been identified recently as a 
p5i -homolog gene. In this study, we analyzed the possible involvement of this gene in 
HCC. We investigated both the expression and structure of p73 gene in HCC for 
possible alterations.We first developed a novel method to analyze the expression of 
alternatively spliced transcripts of p73 (p73a and p73p) simultaneously. This 
technique, based on RT-PCR, allows the analysis of p73 transcripts semi-quantitatively. 
We found that p73a was expressed ubiquituously in 8 cell lines derived from normal 
liver or HCC tumors. Interestingly, p73|3 was present only in 5 differentiated but not in 
3 undifferentiated cell lines. The differentiation status of these cell lines were tested by 
the analysis of albumin and a-fetoprotein transcripts by RT-PCR. These transcripts 
were present in 3/5 differentiated but not in 3 undifferentiated cell lines. Next, we 
screened 25 HCC samples for possible mutations of p73 gene at selected exons with 
non-radioactive heteroduplex test, radioactive SSCP analysis, restriction enzyme 
analysis and DNA sequencing. No alterations were found in exons homologous to those 
of p53 known to harbor mutational hotspots.From these observations, we conclude that 
i) /3 gene is not mutated in HCC, but it may play a critical role in hepatocellular 
differentiation. As p73p was found in differentiated cell lines, this form may be 
involved in transcriptional regulation of liver-specific genes. Additional studues are 
needed to confirm this hypothesis.
ÖZET
KARACİĞER KANSERİNDE p73 GENİNİN ANALİZİ
Necati Fındıklı
Moleküler Biyoloji ve Genetik Yüksek Lisans
Tez Yöneticisi: Prof. Dr. Mehmet Öztûrk
Ağustos 1998
Hepatoselüler karsinom (HCC) dünyada sekizinci en yaygın kanserdir. 
Epidemiyolojik olarak araştınimış risk faktörleri arasında hepatit B virüsü (%80’den 
fazla), hepatit C virüsü ve aflatoksinler başta gelmektedir. Hepatoselüler karsinogenezin 
moleküler mekanizmalan çok iyi bilinmemektedir. Bu tümörlerde sıkça rolü olduğu 
saptanan tek gen p53 tümör baskılayıcı genidir. Ancak, bu genin mutasyonu ya da 
inaktivasyonu HCCTerin yaklaşık %30’unda gözlenmiştir. Hepatoselüler 
karsinogenezin tam olarak anlaşılabilmesi için diğer genlerin de incelenmesi 
gerekmektedir. p73 yakın zamanda p53-homoloğu bir gen olarak bulunmuştur. Bu 
çalışmada, bu genin hepatoselüler karsinomdaki olası rolü araştınimıştır. p73 geninin 
HCC’deki yapısı ve ifadesi, olası değişimler açısından incelenmiştir. Önce p73’ün 
alternatif olarak ifade edilen iki transkriptini (p73a ve p73Ş) ayni zamanda incelemek 
için yeni bir yöntem geliştirilmiştir. RT-PCR’a dayanan bu teknik, p73 transkriptlerinin 
miktannı kabaca belirleyebilmektedir. Böylece HCC tümörlerden ve normal 
karaciğerden türetilmiş 8 hücre hattında p73a’nm ifade edildiği gözlenmiştir. Buna 
karşılık p73p sadece 5 farklılaşmış hücre hattında görüldü. Farklılığını yitirmiş 3 hücre 
hattında ise p73p bulunamadı. Bu hücrelenin farklılaşma durumlan RT-PCR tekniği ile 
albümin ve alfa-fetoprotein transkriptleri incelenerek test edildi. Bu transkriptler 5 
farklılaşmış hücrenin 3’ünde görüldü ancak 3 farklılığını yitirmiş hücre hattında 
görülmedi. Daha sonra, 25 HCC örneği p73 geninin seçilmiş ekzonlanndaki olası 
mütasyonlan belirlemek amacıyla non-radyoaktif heterodupleks testi, radyoaktif SSCP 
analizi, restriksiyon enzim analizi ve DNA dizi analizi yöntemleri ile tarandı. p53 
geninin en çok mütasyona uğradığı bilinen ekzonlanna benzerlik gösteren p73 
eksonlannda mutasyon bulunmadı. Bu gözlemlerden yola çıkarak, p73 geninin HCC’de 
mütasyona uğramadığı, ama hepatoselüler farklılaşmada kritik bir rol oynayabileceği 
sonucunu çıkardık. p73Ş sadece farklılaşmış hücrelerde görüldüğünden, bu form 
karaciğere-özgün genlerin RNA ifadesinin düzenlenmesinde rol oynayabilir. Bu 
hipotezin ek çalışmalarla doğrulanması gerekmektedir.
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1-INTRODUGTION
1.1. Molecular pathogenesis of HCC and role of p53
Hepatocellular carcinoma (HCC) which stems from the malignant transformation 
of liver cells called hepatocytes is one of the most common human tumors throughout 
the world. HCC itself accounts for 85% of primary liver cancers and shows very wide 
geographical variation in incidence (Figure 1.1.). In the Far East and Sub-Saliaran 
Africa, it is a major public health problem. Surgical cure is not possible for most of the 
cases and the cancer is associated with poor prognosis (Harris CC., 1990; Okuda K., 
1992).
Although the molecular mechanisms of hepatocarcinogenesis are poorly understood, the 
risk factors for the development of HCC are now well recognized and some of the steps 
involved in the molecular pathogenesis of HCC have been elucidated in recent years.
Figure 1.1.: Worldwide incidence of hepatocellular carcinoma
Most HCCs develop as a result of chronic liver disease induced by hepatitis B 
virus (HBV) or hepatitis C virus (HCV). Chronic exposure to aflatoxins and certain 
metabolic diseases of the liver also cause HCC. (Figure 1.2.). In both cases resulting 
genetic mutations are common events before hepatocellular carcinoma develops 
(Wands JR., 1995).So far, the most extensively studied etiological factors are HBV, 
HCV and certain toxins ingested via contaminated food. In sub-Saharan Africa and 
certain parts of Asia including Japan relatively high number of the HCC patients carry 
serological markers of hepatitis B virus (>90% for southern Africa; Wands JR., 1995). 
Although the mechanisms by which HBV enhances hepatocellular carcinogenesis are 
not well defined, insertional mutagenesis has been suggested but appears to be 
important only in the woodchuck model in which insertional activation of N-myc gene 
is common (Fourel et al., 1990). In human HCC, only a few hepatomas have been 
found with viral integration near genes associated with growth control (for example 
cyclin A) and differentiation (for example retinoic acid receptor; Wang et al., 1992; 
Dejean et al., 1986). It has also been suggested that viral protein HBx, encoded by 
Figure 1.2. Factors involved in the pathogenesis of HCC.
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hepatitis B virus may act as an effector of cellular transcription factors (Maguire et al, 
1991) or may inactivate the function of p53 by sequestering the protein in the 
cytoplasm (Henkler et al.,1995; Elmore et al., 1997; Ueda et al., 1995).
Like HBV, percentage of HCC patients infected by HCV varies from population 
to population and depends in part on the exposure of general population to this virus. In 
that marmer, HCV appears to be a major cause of HCC in Japan, Italy, and Spain 
whereas it seems to play a less important role in South Africa and Taiwan where HBV 
is predominant. So far, there is no evidence to suggest that HCV has a direct role in the 
molecular pathogenesis of HCC. HCV is associated with this disease by its ability to 
produce chronic liver injury, followed by regeneration and the eventual development of 
cirrhosis (Colombo et al., 1991; Liang et al., 1993; Raedle et al., 1997).
Many attempts have been made to characterize the chromosomal abnormalities 
in HCC, although karyotyping of primary HCC was difficult and achieved only in 
limited cases (Bardi et al., 1992; Simon et al., 1990) including HCC cell lines in which 
a high rate of aneuploidy was detected (Chen et al., 1993). In HCC, chromosome gains 
especially chromosomes 4, 6, 7, 8, 16 and 17 were observed whereas total chromosome 
loss was seen more rarely. Multiple abnormalities of chromosome 1 was noticed. 
Aberrant chromosome number, as well as deletions and translocations that resulted in 
loss of the distal region were described (Yeh et al., 1994). Chromosomal regions 
including 4q, 5q, lOq, lip , 13q, 16q and 17p and 22q have frequently been found to 
show allelic losses, chromosome 17p in which p53 tumor suppressor gene resides 
giving the highest rate. As in the case of p53 in 17p, these losses or alterations in 
chromosome number and the regions may reveal the genes that are important for the
HCC development (Simon et al., 1991; Takahashi et al., 1993; Yeh et al., 1994; 
Zimmermann et al., 1997).
Activation of known protooncogenes such as Ki-ras, N-ras and IGF2 does not 
seem to play an important role in HCC, however in several cases, amplification and 
over expression of cyclin D1 has been reported (Takada et al., 1989; Tsuda et al., 1989; 
Zhang et al., 1993; Nishida et al., 1994).
Among the known tumor suppressor genes, only a few of them have been tested 
for the possible involvement in HCC. So far, the most extensively studied tumor 
suppressor gene is p53 gene, which encodes a nuclear phosphoprotein that acts as an 
important factor in the control of normal cell proliferation. It has been reported that 
this gene shows genetic aberrations in 30% of the hepatocellular carcinomas. It has also 
been reported that HCC-specific codon 249 mutation of p53 is frequent in geographic 
areas where there is a high risk of exposure to aflatoxin p i, which is a known mutagen 
inducing G“> T transversions (Bressac et al., 1991; Hsu et al., 1991; Ozturk et al., 
1991; Aguilar et al., 1993; Fujimoto et al., 1994). HCC samples from other regions 
show low frequency of p53 mutations and codon 249 mutation is rare or absent. (De 
Benedetti et al., 1995; Debuire et al., 1993; Kubicka et al., 1995; Kazachkov et al., 
1996; Unsal et al., 1994).
As another important tumor suppressor gene, retinoblastoma gene (RBI) has 
been reported to show frequent loss of heterozygosity (LOH) and loss of expression. 
RBI mutations have been described only rarely. This could be due to the very large size
of the gene which is difficult to study systemically (Farshid et al., 1994; Hada et al., 
1996; Puisieux et al., 1993; Friedman et al., 1997).
pl6/INK4A /MTSl gene, which was found to show germ-line mutations in half 
of the familial melanomas, has also been reported to show rare germ-line and somatic 
mutations in HCC. The loss of pl6 protein expression was also reported for several 
HCC cell lines (Kita et al., 1996; Piao et al, 1997; Biden et al, 1997; Chaubert et al, 
1997; Kaino et al, 1997; Bonilla et al, 1998). Finally, pl6/INK4A/MTSl gene 
promoter was shown to be silenced by de novo méthylation. This type of inactivation is 
frequently observed in human cancers including hepatocellular carcinoma (Merlo et al, 
1995; Chaubert et al, 1997).
Another gene that is reported to be mutated in HCC is the mannose-6- 
phosphate/insulin-like grov^h factor-Il receptor (M6P/IGF2R) gene. Its gene product 
plays a role in the activation of the TGFP and the degradation of IGF2 (De Souza et 
a l, 1995; Piao et al, 1997).
Compared to other genes, it appears that p53 gene plays an important role in 
hepatocarcinogenesis. But so far, p53 has been found to be mutated in 30-50% of the 
cases. The remaining 50% of the cases can be attributable to the other gene(s) that play 
critical roles in liver carcinogenesis. Other genes with p53-like activity could also be 
involved in HCC development. p73 has been identified recently as a new relative of p53 
gene (Kaghad et al, 1997). Although there is not enough data about its implications in 
cancer as well as its cellular function, its high homology to p53 suggests that it can also 
play an important role in cancer. The study of p73 in HCC was interesting because this
gene is located at chromosomal locus lp36 which is known to be deleted in HCC (Yeh 
et al., 1994). Before presenting the aim of our work, we will summarize the present 
state of literature about p53 and p73 with a specific emphasis on HCC-related 
observations.
1.2. p53 tumor suppressor gene and cancer
p53 protein was discovered in 1979 by different groups as a cellular antigen 
associated with the large T viral antigen of the simian 40 tumor virus (Deleo et al., 
1979; Linzer et al., 1979). Later, a murine p53 cDNA was cloned and this clone was 
found to immortalize cells in vitro or transform primary fibroblasts together with ras. 
These initial observation led to the mis-classification of p53 as a dominantly acting 
oncogene (Jenkins et al., 1984; Parada et al., 1984). However, subsequent studies 
showed that this particular mouse cDNA was mutant and that wild-type p53 was a 
tumor suppressor gene (Eliyahu et al., 1988; Hinds et al., 1989). Also it was showed 
that normal p53 gene product negatively regulates cell growth of some cells (Mowat et 
al., 1985) and abolishes the tumorigenic potential of a cell line in culture (Chen et al., 
1985). Hovewer, growth advantage has been observed in the presence of wild- 
type/mutant genotype as compared with the two wild-type possessing controls 
(Srivastava et al., 1993) indicating that the mutant protein can act as a dominant 
negative by forming multimeric complexes with wild-type p53 gene product and 
inhibiting its normal role in a cell (Milner et al, 1991).
During the last ten years, many observations from different laboratories have
established the fact that p53 is the most frequently mutated gene in human cancer. The
mutation spectra of p53 shows differences in frequency, distribution and nature (Figure
6
1.3.). Distribution of mutations in different exons is shown in figure 1.4. In this picture, 
it is clear that the percentage of missense mutations resulting in the inactive protein is 
relatively higher in the exons that span consensus DNA binding domain (82%) than 
Figure 13.; Worldwide distribution of cancers and p53 mutation rates
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those encoding the acidic transactivation domain and the basic carboxy terminal domain 
(Wang et al., 1997).
Figure 1.4. Distribution of p53 mutations in different exons
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G:C-^ A:T base transitions represent about 40% of all p53 mutations in human 
cancers. These changes occur at CpG dinucleotides in about 60% of the cases and they 
seem to arise from spontaneous deamination of 5-methylcytosine, which yields thymine 
(Greenblatt et al., 1994). In HCC, the conversion of G;C·^ T:A is found to be much 
more common than any other base changes as shown in figure 1.5. (Soussi T., 1997). 
Moreover, this conversion was found to be a specific G-> T transversion of the third
base of codon 249, leading to a substitution of arginine to serine in a significant number 
of patients from southern Africa and the Qidong area in China (Bressac et al., 1991; 
Hsu et al., 1991). It was suggested that this mutation was associated with high aflatoxin 
B1 intake in food and may have contributed to the high incidence of HCC in these 
areas. This finding is also supported by in vitro studies in which p53 codon 249 was 
preferentially targeted to form adducts with aflatoxin B1 (Aigular et al., 1993; Figure 
1.6.). It is important to note that five of the six mutation hotspots (Codons 175, 245, 
248, 249, 273, and 282) in the p53 gene occur at CpG nucleotides. These hotspots 
encode arginines at sites that are essential for the maintenance of contact between the 
protein and its DNA consessus sequence: this contact in turn responsible for DNA 
binding and transactivation (Cho et al., 1994).
P53 protein was also found to complex with viral proteins (SV40 large T 
antigen, adenovirus ElB and HPV type 16 E6 protein) and such complexes of p53 were
Figure 1.5.: Comparison of distribution of base changes between all 
cancers and HCC
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found to be inactive (reviewed by zur Hausen H., 1996). Thus, functional inactivations 
of p53 also appears to be frequent in cancers, as it will be discussed later in detail. 
Figure 1.6. p53 hotspots in all cancers and in HCC.
1.3. Cellular functions of p53
Possible biological functions of p53 have been studied by different groups and 
the results published so far indicate multiple cellular functions such as the control of 
cell cycle checkpoints, genetic stability (Kastan et al., 1992) and the initiation of 
programmed cell death or apoptosis (Figure 1.7 ). All of these p53 functions are 
possibly related to its ability to act as a powerful tumor suppressor gene. Experiments 
show that initiation events which triggers the p53 response can be DNA damage,
activated oncogenes or certain stress conditions. It is crucial to point out that p53
10
response generated by such signals can differ in different cell types or in the presence of 
different extracellular signals (Lane DP., 1992).
Figure 1.7. p53 response pathways
Following DNA damage, p53 is activated and it transactivates a number of 
downstream genes whose products contribute to the cellular response to DNA damage 
with diverse biological activities. The following genes are the most important p53 
target genes: p21 (El-Diery et al., 1993), mdm2 (Wu et al., 1993), GADD45 (Kastan et 
al.,1992; Sun et al.,1995) , HIC (Vales et al.,1995), cyclin G (Okamoto et al.,1995; 
Zauberman et al.,1995), Bax (Miyashita et al.,1995), proliferating cell nuclear antigen 
(PCNA; Shivakumar et al.,1995), IGF-BP3 (Buckbinder et al., 1995), hMSH2 (Scherer 
et al., 1996) and BTG2 (Rouault et al., 1996). The products of these genes were shown 
to have a direct effect on cellular growth, DNA repair or DNA replication. p53 binds to
11
specific p53-responsive elements on either the promoter or intronic regions in these 
genes and these responsive elements are outlined in table 1.1.
Other candidates for the p53 response genes are TGF-a, thrombospondin-1, 
fas/APOl, Rb, EGF receptor, cyclin D and p53 itself. Other target genes will continue 
to be identified as the roles of p53 in cellular metabolism becomes more clear (Ko LJ. 
and Prives C.,1996).
Table l.L: p53-responsive elements of target genes
'?pne:·
' •c '/· '
Position*.'. Sequences:
(Pii Pu Pii C A/T T/A G Py Py Py) (0-13 bp apart)
p21 2303 GAACATGTCC CAACATGTTC
GADD45 3832 AGACCTGCCC GGGCAAGCCT
Bax 488 TCACAAGTTA AGACAAGCCT
MCK 119 TGGCAAGCCT TGACATGGCC
Cyclin G 262 AGACCTGCCC GGGCAAGCCT
IGF-BP3 5064 (intron I) AAACAAGCCA CAACATGCTT
5983 (intron I) GGGCAAGACC TGCCAAGCCT
hMSH2 447 AGGCTAGTTT AAGTTTCCTT
MDM2 139 GGTCAAGTTG GGACACGTCC
BTG2 97 AGTCCGGGCA AGCCCGAGCA
* Position of the response sequence according to Genbank’s map positions
One of these downstream genes is p21, the CDK2 inhibitor (also known as 
universal CDK inhibitor) that inhibits the activity of cyclin-dependent kinases. 
Experimentally, a p53-dependent inhibition of cyclin E/CDK2 was observed in 
fibroblasts and this inhibition was shown to be mediated p21. Recently developed p21 
null mice showed a normal developmental pattern but mouse embryo fibroblasts that 
lack p21 were partially deficient in their ability of G1 arrest in response to DNA 
damage. This observation is another confirmation of the importance of p21 in G1
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checkpoint. It has been implied that contribution of p53 into G1 checkpoint is to 
preserve the genetic stability. In the absence of p53, genomic instability results 
from checkpoint loss creating gene amplifications, aneuploidy and other chromosomal 
aberrations (Smith et al., 1995).
However, p21-independent cell cycle arrest also exists (Deng et al., 1995; 
Bmgarolas et al., 1995). Fibroblasts with elevated p53 expression also causes minor G2 
anest. Furthermore wild-type p53 overexpression in a human ovarian cancer cell line 
resulted in a transient G2 delay (Vikhanskaya et al., 1994). So it has been suggested 
that in addition to G1 cell cycle arrest, p53 also participates G2 cell cycle checkpoint 
and length of this arrest duration is dependent on cell type (Kastan et al., 1991).
p53-dependent apoptosis was first detected in experiments using myeloid
leukemic cell lines with overexpressed exogeneous wild-type p53. In these experiments,
the cell viability was rapidly lost, in a manner characteristic of apoptosis (Yonish et al.,
1991). From the reverse approach, thymocytes isolated from p53-deficient mice did not
undergo apoptosis after ionizing radiation as compared with the normal thymocytes
confirming the involvement of p53 in physiological apoptosis process (Lowe et al.,
1993). Recently it was shown that expression of bax is induced in slow growing
apoptotic tumors indicating the role of p53-induced bax gene (Yin et al., 1997).
Furthermore tumour growth is accelerated and the apoptotic ratio drops by 50% in bax-
deficient mice, suggesting the requirement of bax for a full p53-dependent response
(Yin et al.,1997). Under conditions such as highly damaged nuclear DNA and absence
of required survival factors, certain cell types are observed to go through p53 dependent
programmed cell death with the possible function of elimination of unstable genomes
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and inadequately-fed cells, diminishing the probability of having cancerous phenotype. 
Beside the involvement of Bax gene in the p53-dependent apoptosis, recently, it has 
been proposed that p85 protein, which is the regulatory subunit of pi 10 PI(3) kinase, is 
upregulated by p53 under oxidative stress conditions leading to cell death and this 
involvement is independent of PI(3)K (Yin et al., 1998).
A recent study utilized the oncogenic ras that was formerly shown to transform 
immortal rodent cells to a tumorigenic state and in this study it was found that the 
expression of oncogenic form of the ras in primary human or rodent cells resulted in a 
permanent G1 arrest, in which the accumulation of p53 and pl6 was observed. Also, 
disruption of either p53 or pl6 was shown to abolish the ras induced growth arrest, 
concluding that oncogenic ras provokes premature senescence in primary rodent and 
human cells in association with the induction of p53 and p i6. This suggests that besides 
other functions, p53 has an important role in the induction of the senescence program 
(Serrano et al., 1997).
Most of the experiments, performed to analyze the possible role of p53 in
differentiation and development, were done using cells of the haemopoietic lineage.
When wild-type p53 is overexpressed in early pre-B cell line, the cytoplasmic p. heavy
chain and B-cell specific antigen which are the indicators of more mature stage are
expressed (Shaulsky et al., 1991). Likewise, a Friend erythroleukemia cell line
overexpressing wild-type p53 is observed to start expression of hemoglobin, a marker
of erythroid differentiation (Johnson et al., 1993). Together, these reports can be
interpreted that p53 is involved in haemopoietic development. The mechanism may not
be through a direct induction of differentiation but the differentiation could be
14
facilitated by the inhibitory action of p53 in cell cycle (Hu et al., 1995). It has been 
described that p53 knock-out mice shows a normal viable development; but in another 
experiment a fraction of the p53-deficient embryos displayed neural tube defects (Sah 
et al., 1995). Thus, p53 may also be involved in the development and differentiation 
independently of its ability to act as a tumor suppressor.
1.4. Biochemical characterization of the p53
Human p53 gene covers 16-20 kb of DNA in chromosome 17pl3, having 11
exons. Exons between 2 and 11 encodes an mRNA of 2,2-2,5 kb that is translated into a
protein of 53 kDa with 393 amino acids. The protein contains five distinct
evolutionarily conserved boxes numbered as I-V and the residues between II to V are
encoded by exons 4 to 9. Most of the p53 mutations occur in this region. p53 protein
has several distinct structural domains (Figure 1.8.) one of which resides in N terminus
and contains acidic transcriptional activation domain that interacts with the
transcription initiation machinery. Next to transcriptional activation domain, there is a
proline-rich region. This hydrophobic domain appears to be important for the
maintaining the overall structural stability of p53 protein (Levine et al., 1991).
Recently, this domain was shown to be involved in p53-mediated apoptosis (Ruaro et
al., 1997). The central portion of p53 located between amino acids 120-290 is the DNA
binding domain. This domain recognizes a specific DNA motif (5 - Pu Pu Pu C A/T
T/A G Py Py Py) which is repeated on target genes and shown in table 1.l.(El-Deiry et
al.,1992; Zambetti et al., 1992). Another charged basic domain through C-terminus
was found to be essential for the tetramerization (Iwabuchi et al.,1993) and subsequent
nuclear transport signal containing region resides between amino acids 316 and 325
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(Shaulsky et al.,1990). At the very end of the carboxy-end a regulatory domain is found 
and this domain regulates the activation of the wild-type TP53. This last domain is 
absent in protein product of an alternatively spliced mRNA of p53 (Wolkowicz et al.,
1995)
Figure 1.8.: Functional domains of TP53
R248 R273
T ranscriptionaf 
activation 
domain
Sequence Specific DNA binding 
domain
PKC site CKII site 
^393
Regulatory domain
Recent studies about the transcriptional activation and repression functions of 
p53 have revealed that the consensus p53 response element plays a crucial role. The 
genes which have this sequence are transcriptionally activated by p53 and the absence 
of the response element is thought to be sufficient for the repression. The key 
mechanism that mediates the activation/repression process involves TATA-binding 
protein (TBP). Experiments show that TBP interacts with both the amino and carboxy 
terminus of p53 and it is proposed that this difference plays a switching role between 
p53-dependent transcriptional activation and repression of target genes (Horikoshi et 
al., 1995).
1.5. Inactivation and activation of p53
p53 function can be inactivated in several ways one of which is the mutation 
that occur on p53 gene in nearly 60% of all human cancers (Hollstein et al., 1991;
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Greenblatt et al., 1994). In most cases, only the mutant allele is detected in tumor cells. 
Thus, the loss of wild type allele in most cases is followed with a mutation on the other 
allele. Vast majority of missense mutations are clustered in the sequences encoding 
the central region of the p53 protein. The analysis of p53 crystal structure and mutation 
distribution patterns has revealed that p53 mutational hotspots are on amino acid 
residues involved in DNA binding. Two of them abolish the p53 DNA binding 
function (residues 248 and 273) and the remaining four (175, 245, 249 and 282) 
interfere with the stabilization of the protein-DNA interaction (Cho et al., 1994). 
Analysis of p53 mutation databases showed that, with more that three thousand 
different mutations collected from the human tumor cell lines, different tumor types 
have distinct p53 mutation profile. These profiles are very helpful in understanding the 
cancer aethiology, clinical basis of tumorigenesis and functions of p53 domains.
Another mechanism for the loss of p53 function is the inactivation of the protein
by viral proteins. p53 has been shown to form complexes with the SV40 large T antigen
(Linzer DI. and Levine AJ..,1979), adenovirus type 5 ElB 58 kDa antigen (Samow et
al., 1982; Zantema et al., 1985; Braithwaite et al., 1991) and the E6 protein of human
papilloma virus type 16 (HPV-16; Wemess et al., 1990). The region of p53 bound by
large T antigen closely correlates with the conserved core domain and is contained
within residues 94 to 293. This large T antigen-p53 complex inhibits p53 mediated
transcriptional activation by inhibiting DNA binding as it is shown by in vitro
experiments. Similarly ElB, one of the genes encoded by adenovirus, forms a complex
with p53 and inhibits transcriptional activator function but binding of this molecule to
p53 does not prevent its DNA binding ability. As different from the ElB and large T
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antigen, the association of E6 protein with p53 targets it effectively for degradation 
through ubiquitin pathway, leading to a deficit of p53 activity for the control of normal 
cell proliferation. (Scheffner et al., 1990).
In addition to these abrogation-in-function states of p53 protein, deregulation of 
p53 activity by the overexpression of cellular proto-oncogene mdm-2 is reported and 
characterized by several groups (reviewed by Oliner JD., 1993; Picksley et al., 1993). 
Ill certain tumors (particularly sarcomas) with wild-type p53 the amplification of mdm- 
2 gene was observed suggesting the alternative inactivation pathway of p53 protein. 
The mdm-2 gene was first identified originally by virtue of its amplification in 
transformed mouse lines. Overproduction of this protein was shown to be tumorigenic 
(Fakkarzadeh et al., 1991). Interestingly, mdm-2 gene is also found to be 
transcriptionally activated by p53 protein and it is proposed that p53 function is 
controlled by p53/Mdm-2 autoregulatory feedback loop where p53 stimulates mdm-2 
expression and its own function is impaired by being sequestered in an inactive p53- 
Mdm-2 complex (Barak et al., 1993; Wu et al., 1993). The main inhibitory role of 
rndm-2 is its ability to bind to the transcriptional activation domain of p53 and to block 
the p53-target gene activation. It was recently reported that mdm-2 also promotes the 
rapid degradation of p53 (Haupt et al.,1997).
p53 protein is extensively modified by phosphorylation (Meek et al., 1994).The 
serine/threonine phosphorylations are clustered into two distinct domains at the N and 
C-termini of the protein and the enzymes that are responsible for this process in vitro 
are found to be DNA dependent protein kinase (DNA-PK), casein kinase I-like enzyme
and casein kinase Il-like enzyme (Fiscella et al.,1993).
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In most cells, wild-type p53 is present in extremely low quantities and has a 
short half-life (6-20 minutes). Ionizing radiation or UV light and alkylating agents 
induce p53 and the presence of DNA strand breaks is critical for this induction (Nelson 
atid Kastan 1994). It is generally agreed that the inductive response is post- 
transcriptional (Kastan et al., 1991; reviewed by Ko and Prives, 1996).
Also, recently identified factor ref-1, previously named as redox/repair protein, 
wa.s found to be an extremely potent activator of the latent p53 protein. It was further 
stated that ref-1 stimulates p53 both in redox-dependent and redox independent manner 
in vivo and in vitro suggesting that this factor may play a critical sensor role for the 
genotoxic stress that can activate latent p53 (Jayaraman et al., 1997).
Vaziri et al. investigated the possible relationship between the telomere loss and 
the p53 activity and they concluded that in ataxia-telengiectasia fibroblasts which show 
accelerated telomere loss and premature senescence when compared with normal 
fibroblasts also shows increased specific activity of p53. It has further been shown that 
p53 can associate with PARP (poly ADP-ribose polymerase) and inhibition of PARP 
activity leads to abrogation of p21AVAFl and mdm2 expression in response to DNA 
damage. So p53 can not only be activated in response to DNA damage but also in 
response to telomere shortening (Vaziri et al., 1997).
In summary, p53 protein is transcriptional activator which upregulates the
functions of several genes involved in the control of cellular growth. Under normal
conditions p53 has a short half-life. Following DNA damage (X-rays, DNA alkylating
agents etc.) p53 protein is stabilized and accumulates in cells leading to its
transcriptional activation. One of the p53 target genes, p21 encodes an inhibitor of
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cyclin-dependent kinases, inducing cell cycle arrest at both G1 and G2/M phases. p53 
induces apoptosis in certain cells either directly or by the induction of bax expression. 
In tumor cells, this role of p53 is lost either by mutational inactivation or functional 
inactivation.
1.8. Identification and characterization of p73 gene
p73 gene is a newly discovered gene that shows considerable homology with 
p'fl tumor suppressor gene (Kaghad et al.,1997). Interestingly, the gene was identified 
while pursuing research into growth factors called cytokines. The group was 
performing a hybridization screen of a COS cell cDNA library using degenerate 
oligonucleotides corresponding to IRS-1 binding domains. Coding sequence gave no 
considerable homology with IRS-1 binding domain sequence but later it was found that 
the molecule shows homology with p53 in both aminoacid and DNA sequence (figure
1.9.),
For almost 20 years, many researchers were searching for the possible homologs
of p53 since many oncogenes and tumor suppressor genes found so far exist as a family 
like myc (c-myc, N-myc and L-myc), ras (H-ras, K-ras and N-ras) and Rb (Rb, p i05 
and p i30) family of genes. Suprisingly all the low stringent hybidization and 
degenerate PCR techniques gave no positive results. This negative results led people to 
think that p53 function was unique and there was no redundant genes. The discovery of 
p73 demonstrated that, p53, like many other genes, belong to a family which shows 
structural and probably functional similarities (Oren M., 1997).
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Figure 1.9.: Homology between p73a and p53
p53 MAj^--TATS|D GGT||EH^S sIePDSTYFD LPQSSRG||^E WGGTDSSi
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vfh|egmtts vma|fnllss tm|qmssraa s|s|yt|eh| |sv|ths|ya
DLMI---SPD DIElWFTEDP Gp|eAPRMPE a|p|va1ap| |pt|a -aIaP
QHSTFDTMS PAPVI^TD YP|PHH|EVT iQQlsiAKiA |w|ys|l|k| 
^PL----- SSSViiQKT YqIsYgIrLG iLHiGi^V IcMsiAiNi
MF^LUrci VlLWlDSTil »RviliAI H oSOHmIeI
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GCPNCIEYFT SQGLQSIYHL QNLTIEDLGA LKIPEQYRMT IWRLGQDLKQ
GHDYSTAQQL LRSSNAATIS IGGSGELQRQ RVMEAVHFRV RHTITIPNRG
GPGGGPDEWA DFGFDLPDCK ARKQPIKEEF TEAEIH
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p73 gene shows similarities and differences with p53 tumor suppressor gene in 
several aspects. It is localized in chromosome lp36 and has 14 exons. It has two 
splicing variants differing at their C termini, termed as p73a and p73p (lacks 96 
nucleotides corresponding to exon 13) respectively. It is also reported that there exists a 
third form of p73 protein resulting from the alternative start codon at the N terminus. 
P73a form codes for a protein of 636 amino acids long whereas |3 form , due to exon 13 
deletion, yields a polypeptide with 499 amino acids (Figure 1.10.). On the other hand, 
p53 gene resides in short arm of chromosome 17. Although they are mapped to 
different chromosomes, the organization of these two genes are similar in exonic 
structures and coding / non-coding parts (In both, exon 1 is non-coding e.g.). Since p73 
has a longer ORF, the resulting transcript sizes of two forms are 4.4 kb and 2.9 kb 
whereas p53 has a transcript size of 2.5 kb.
Figure 1.10.: p73 variants.
p73a
1.7. Functional and structural similarities between p53 and p73
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According to the protein product, p73a and p73p forms, though they are 
longer than p53, resemble the latter in three regions; N terminus, which is responsible 
for transcriptional activation, is 29%; DNA binding domains are 63% and 
oligomerization domain is 38% identical. Furthermore, the amino acid residues that are 
frequently found to be mutated in variety of cancer types (R175, G245, R248, R249, 
R273 and R282 which are also shown in purple in figure 1.9.) are also conserved in 
p73. No significant homology was reported between the C-terminal domain of 
mammalian p53 and p73 indicating that this unique region might be responsible for the 
interaction with other factors that cooperate with p73 or regulate its function(s). 
However, this C terminal region of p73a form is similar to invertebrate p53 homologs 
and this opens another debate about the evolution pattern of p53 gene. It has now been 
speculated that p53 may have evolved from a p73-like gene.
Also, p53 and p73P (but not the p73a) have been shown to form homo­
oligomers in yeast two-hybrid assays. In these experiments it has also been observed 
that p73P showed significant but relatively weak interactions with p53 but the actual 
existance of these mixed oligomers in vivo still needs to be determined.
Another important finding about p73 is that, it transcriptionally activates 
one of the main p53 target genes p21AVAFl in transient-transfection experiments. 
Interestingly, when the Arg residue of p73 at position 292 (which is analogous to Arg 
residue at position 273 of human p53 gene) is mutated to His, this p73-dependent
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activation of p21AVAFl is abolished. Arg 273 in p53 has been shown to be mutated in 
variety of cancer types and this change abrogates the ability of p53 to act as a 
transcriptional activator (Kaghad et al., 1997).
Although overexpressed p73 has been shown to induce apoptosis, the 
mechanism is not well understood. The analysis of apoptosis-asociated genes such as 
bax and Fas/Apol are needed to clarify the role of p73 in apoptotic response (lost et al., 
1997).
1.8. Aim of the project
Molecular pathogenesis of HCC remains poorly understood. High frequency of 
p53 mutations in HCC cells and possible functional inactivation by Hbx of HBV virus 
suggest that one major pathway of hepatocellular carcinogenesis is the inactivation of 
tiepatocellular functions mediated by p53. However, p53 is found to be mutated in 30% 
of these tumors. The malignant transformation of other HCCs might be due to gene 
aberrations other than p53 mutations. The chromosome location of p73 (lp36) was 
known to be frequently altered in HCC. This is why we decided to study whether HCC 
cells display aberrations of p73 gene. If so, this would help to find another pathway of 
malignant transformation of HCC mediated by the loss of p73 function. Before starting 
any functional studies of p73 in hepatocytes and HCC cells, it was important to know 
whether p73 gene expression is lost or modified by genetic mutation. We decided to 
study first the expression of p73 in HCC cells and then the primary tumors for possible 
mutations in p73 gene by using non-radioactive heteroduplex test, radioactive SSCP 
analysis, restriction enzyme analysis and DNA sequencing.
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2-MATERIALS AND METHODS
2.1. MATERIALS
2.1.1. Cell lines and primary tumor samples
The following cell lines were used in this study; HT29 (Huet et al., 1987), 
Chang (Chang RS., 1954), WRL68 (Apostolov K., U.S. Pat.:3,935,066 ), Mahlavu 
(Alexander JJ., 1984), Hep3B (Aden et al., 1979), Hep3B-TR (Hasegawa et al., 1995), 
HepG2 (Aden et al., 1979), FOCUS (He et al., 1984) and PLC/PRF/5 (Alexander et al., 
1976). All cell lines were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal calf serum, glutamine (2 mM), non-essential 
amino acids, penicillin and streptomycin. All cell lines were negative for mycoplasma 
contamination except PLC/PRF/5 and Mahlavu.
DNA samples from primary HCCs have also been studied. These samples have 
been collected from different geographical locations in the world. They have been 
previously studied for their status of p53 gene and HBV DNA sequences. The data on 
patients (age, sex, viral markers etc.) was also known (Unsal et al., 1994).
2.1.1. Chemicals
NAME: PRODUCER:
Agarose Prona basica
Ammonium persulfate Carlo Erba
Boric acid Sigma
Bromo phenol blue Sigma
DMEM Sigma
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DNA ladder, 1 kb MBI Fermentas
MgCl  ^(25 mM) Promega
Reverse transcription lOX buffer Promega
dNTP mixture (10 mM) Promega
Rec. Rnasin© ribonucléase inhibitor Promega
AMV reverse transcriptase Promega
OIigo(dT)i5 Primer Promega
DNA ladder, 100 bp MBI Fermentas
dNTP mix (10 mM) MBI Fermentas
Dulbecco’s PBS Biological
EDTA Sigma
Ethidium bromide Sigma
Formamide Cario Erba
Formaldehyde Cario Erba
Gel extraction kit Qiagen
Glycerol Cario Erba
Guanidium thiocyanate Merck
L-Glutamine Biochrom-Seromed
Non-essential amino acids Biological
Nusieve agarose FMC
""P dCTP Izotop
Penicillin streptomycin B iochrom- S eromed
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Phenol Merck
Sodium acetate Carlo Erba
Sodium chloride Carlo Erba
Sodium Hydroxide Carlo Erba
Taq DNA Polymerase MBI Fermentas
lEM ED Sigma
Trypsin-EDTA Sigma
Xylene cyanol FF Sigma
2.1.3. Stock solutions and buffers
SOLUTION METHOD OF PREPARATION
For Agarose Gel Electrophoresis:
5X formaldehyde gel running buffer Add 10 ml of 2M sodium acetate and 10.3 gr
of MOPS into 390 ml of DEPC-treated water. 
Dissolve and adjust the pH to 7.0 with sodium 
hydroxide. Add 5 ml of 0.5M EDTA (DEPC- 
treated) pH:8.0 and fill up to 500 ml with 
DEPC-water.
Add 186.1 g of disodium 
ethylenediaminetetraacetate- 2 H2O to 800 ml 
of dHjO. Stir vigorously on a magnetic stirrer. 
Adjust the pH to 8.0 with NaOH.
EDTA 0.5 M (pH: 8.0)
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Formaldehyde gel loading buffer
TBE lOX
Ethidium Bromide (10 mg/ml) Add 1 g of ethidium bromide to 100 ml of
dHoO. Stir on a magnetic stirrer for several 
hours to ensure that the dye has dissolved. 
Wrap the container in aluminum foil or 
transfer the solution to a dark bottle and store 
at room temperature.
Prepare appropriate amount that contains 50% 
Glycerol, 1 mMEDTA (pH;8.0), 0.25%
Brom Phenol Blue and 0.25% Xylene cyanol. 
Dissolve 108 g Iris base and 55 g of Boric 
acid in 800 ml dH20. Then add 40 ml of 0.5 
M EDTA and adjust volume to 1 liter with 
dH20.
For Polyacrylamide Gel Electrophoresis:
Acrylamide 30% Dissolve 29 g of acrylamide and 1 g of N,N’-
methylenebisacrylamide in a total volume of 
60 ml of dHjO. Heat the solution to 37°C to 
dissolve the chemicals. Adjust the volume to 
100 ml with dHjO. Check that the Ph is 7.0 or 
less and sterilize the solution by filtration. 
Store the solution in dark bottles at room 
temperature.
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Acrylamide 50%
SSCP Loading buffer
Ammonium persulfate 10%
For RNA Extraction;
Dénaturation Solution (stock)
Dissolve 49.5 g of acrylamide and 0.5 g of 
N,N’-methylenebisacrylamide in a total 
volume of 60 ml of dH20. Heat the solution to 
37°C to dissolve the chemicals. Adjust the 
volume to 100 ml with dHjO. Check that the 
Ph is 7.0 or less and sterilize the solution by 
filtration. Store the solution in dark bottles at 
room temperature.
In an 50 ml falcon tube add the following in 
an appropriate volume; Formamide 95%
(v/v), bromophenol blue 0,01 (w/v) and 
NaOH (final cone. 10 mM). Store at -20 °C. 
For fresh use: Dissolve 0.1 g of ammonium 
persulfate with 1 ml dH2 0 .
Prepare a stock solution by dissolving 250 g 
guanidium thiocyanate in a solution of 293 ml 
dH20, 17.6 ml of 0.75 M sodium citrate, 
pH:7.0, and 26.4 ml of 10% Sarkosyl at 60°C 
to 65°C with stirring. The stock solution can 
be stored up to 3 moths at room temperature.
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Dénaturation Solution (working)
Phenol, water-saturated
Sodium acetate 2M
Sodium dodecyl sulfate 10% (SDS)
Prepare working solution by adding 0.35 ml 
of 2-ME per 50 ml of stock solution. The 
working denaturing solution can be sotred 1 
month at room temperature.
Dissolve 100 g phenol crystals in dH^O at 
60°C to 65°C. Aspire the upper water phase 
and store up to 1 month at 4°C 
Add 16.42 g of sodium acetate (anhydrous) to 
40 ml dHjO and 35 ml of glacial acetic acid. 
Adjust solution to pH; 4.0 with glacial acetic 
acid and the final volume to 100 ml with 
dH20. The solution is 2 M with respect to the 
sodium ions.
Dissolve 100 g of electrophoresis-grade SDS 
in 900 ml of dHjO. Heat to 68°C to assist 
dissolution. Adjust the pH to 7.2 by adding a 
few drops of concentrated HCl. Adjust 
volume to 1 liter with dHjO.
2.1.4. Plastics aud disposables 
1.5 ml Eppendorf tubes Eppendorf
2.0 ml Eppendorf tubes Eppendorf
30
0.2 ml PCR tubes
10 ul white pipette tips 
200-1000 ul blue pipette tips 
5-200 ul yellow pipette tips 
Falcon tubes (50 ml)
Falcon tubes (15 ml)
Gloves
Parafllm
Sterile plastic pipettes 
Bottle filter system (500 ml) 
75 cm^  straight neck flask 
162 cm^  straight neck flask 
225 cm^  straight neck flask
Perkin Elmer
LP
LP
LP
Costar
Costar
Beybi plastics 
American National Can 
LP
Costar
Costar
Costar
Costar
2.1.5. Apparatus
APPARATUS: PRODUCER:
<1>40 pH meter 
Axiovert 25 Microscope 
Biofuge pico  bench centrifuge 
CS-15R Centrifuge 
DU640 Spectrophotometer
Beckman
Zeiss
Heraeus instruments
Beckman
Beckman
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EC175 Adjustable vertical gel system E-C apparatus corporation
EC250-90 Power supply E-C apparatus corporation
EC350 Midicell Electrophoretic gel system E-C apparatus corporation
EC370M Minicell Electrophoretic gel system E-C apparatus corporation
Geneamp PCR system 9600 thermal cycler Perkin-Elmer
Locator 6 plus  Liquid nitrogen tank Thermolyne
Micro chef microwave Moulinex
Mirak magmetic stirrer Thermolyne
Oligo lOOOM DNA synthesizer Beckman
Pipette 1000 ul Eppendorf
Pipette 20 ul Eppendorf
Pipette 200 ul Eppendorf
Slab gel drier SGD2000 Savant
SpeedVac SCI 10 Savant
Tempette™ TE-8D water bath Techne
The butterfly Cell House 170 Heto
2.2. METHODS
2.2.1. Growth Medium Preparation
DMEM is prepared from lOX concentrated stock solution as follows: 
800 ml dHjO
100 ml 1 OX DMEM
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49.3 ml Sodium bicarbonate 7.5% (pH:7.3) 
fill up to 1 liter with dH,0 
At that stage, DMEM solution can be stored at 4°C.
Add:
10 ml non-essential amino acids
10 ml penicillin/streptomycin
10 ml L-glutamine (200 mM)
100 ml Fetal calf serum
Sterilize the solution by filtration and store at +4°C.
DMEM solution at that state can be used up to 30 days.
2.2.2.Cyropreservation of stock cells and thawing frozen stock of cells 
About 1-2x10® of cells were recovered by 10 ml of DMEM after trypsin 
treatment. They were then spinned at 1500 rpm for 5 minutes. After washing with 10 
ml of PBS, cells were again spirmed down at 1500 rpm for 5 minutes. 2 ml of F- 
medium containing 80% DMEM, 10% DMSO and 20% FCS were added and 
suspension was transferred into freezing vials. Cells were stored at -70 °C for one day 
and then transferred into liquid nitrogen for cyropreservation.
In order to achieve rapid thawing, vials containing frozen cells were transferred 
directly to a 37°C water bath without submerging the cap. Once thawed, vials were then 
sterilized by swapping the outer surface with 70% ethanol. The contents were 
transferred into a sterile plate containing pre-warmed, fresh growth medium with the 
help of a pipette and plated into small flasks. Thawed cells were examined daily using a
microscope and subcultured as soon as confluency was reached.
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2.2.3. Subculturing of cells
Old medium was removed by the help of an aspirator and cells were washed 
with 1-3 ml of PBS. In order to detach the cells from the plate, 0.5-1 ml of trypsin was 
added onto the plate and the plate was incubated at 37 °C for 2-3 minutes to quicken the 
detachment. Cells were then examined under microscope to make sure that all the cells 
were efficiently detached. DMEM was added to a new plate that was sterile and labeled 
(8 ml for 75 cm  ^plates, 25 ml for 225 cm^ plates). 2-3 ml of DMEM was placed over 
the detached cells. After the cells were properly suspended with newly-added medium, 
they were removed, and placed into the new plate.
2.2.4. Total RNA Preparation
Guanidium thiocyanate total RNA isolation method was used (Adapted from 
Chomczynski P., Sacchi N., 1987). The procedure is as follows;
• Cells were washed with 10 ml PBS two times
• 4 ml of dénaturation solution was added
• Cell lysis is aided by mixing with pipette.
• Lysate was then transferred into 15 ml sterile tube
• 0.1 volume of 2M sodium acetate was added
• Mixture was aliquoted into four tubes (4X1 ml)
• 1 ml of water-saturated phenol was added and mixed
• 0.2 volume of 49:1 chloroform/isoamyl alcohol was added and mixed
• Tubes were stored at 4°C for 15 minutes, being resuspended frequently
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• Tubes were then centrifuged at 10.000 rpm for 15 minutes at 4°C.
• Aqueous phase was taken to a fresh tube
• 1 volume of 100% isopropanol was added and mixture was stored at -20°C 
overnight
• Samples were centrifuged at 10.000 rpm for 10 minutes at 4°C
• Supernatant was discarded, pellet was dissolved in 300 ul of denaturation 
solution
• Precipitation was carried out using 300 ul 100% isopropanol
• Samples were stored again at -20°C overnight
• Tubes were centrifuged at 10.000 rpm for 15 minutes at 4°C
• After discarding the supernatant, pellet was dissolved in 75% EtOH
• Tubes were mixed and left for 10-15 minutes at room temperature
• They were then centrifuged again at 10.000 rpm for 15 minutes at 4°C
• Pellet was dried with Speedvac
• Finally, pellet was resuspended in 100-200 ul DEPC-treated water
• Samples were aliquoted and were stored at -70°C by adding 1 ml of EtOH 
and 10 ul of sodium acetate.
2.2.5. Electrophoresis of RNA
Electrophoresis of RNA was performed according to the procedure from 
Molecular Cloning (Sambrook et al., 1989) in which total RNA was loaded and run on 
the agarose gel containing formaldehyde. This method was adapted from those of 
Lehrach et al. (1977), Goldberg (1980) and Seed (1982).
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2.2.5.1. Formaldehyde-containing 1% Agarose Gel
After the casting step, 11 ml of 5X formaldehyde gel running buffer, 35 ml of 
DEPC-treated water and 0.5 g of agarose were added into a beaker and the solution was 
heated in microwave oven until the agarose was melted completely. When the solution 
cooled down to approximately 65°C, 10 ml of formaldehyde was added and the 
mixture was poured into the casted apparatus.
2.2.5.2. Sample Preparation
Extracted total RNAs were diluted to 5ug/ul with DEPC-treated water. Into 
fresh tubes:
4.5 ul RNA
2.0 ul 5X formaldehyde gel running buffer
3.5 ul formaldehyde
10.0 ul formamide
were added and the tubes were incubated at 65°C for 15 minutes for the dénaturation of 
RNA, chilled on ice for 5 minutes and instantly centrifuged . Samples were then loaded 
into the corresponding wells on the gel with the addition of 2.0 ul formaldehyde gel 
loading buffer.
Electrophoresis was then carried out at 70 V for 2 hours at room temperature.
2.2.5.3. Staining and Visualization
After the run, the gel was put into the 0.1 M ammonium acetate containing 0.5
ug/ml ethidium bromide for 30-45 minutes. Then the gel was destained with DEPC-
treated water for at least 30 minutes and the gel was visualized under UV light.
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2.2.6. cDNA Preparation
For cDNA preparation, Promega Reverse Transcription System was used. According to 
the original protocol, into each tube:
1 Ug RNA
4ul MgCl2(25mM)
2ul Reverse transcription 1 OX buffer
2ul dNTP mixture (10 mM)
0.5 ul Recombinant Rnasin© Ribonucléase Inhibitor
15u AMV Reverse Transcriptase
0.5 ug 01igo(dT),5 Primer
and nuclease-free water was added to a final volume of 20 ul.
The reaction was incubated at 42°C for 15 minutes and the AMV Reverse 
transcriptase was inactivated by heating the sample at 99°C for 5 minutes followed by a 
5 minute incubation at 0-5°C.
2.2.7. PCR Amplifîcation
The PCR which was invented by Kary Mullis (Mullis et al., 1987) is an in vitro 
method for enzymatic synthesis of specific DNA sequences, using two oligonucleotide 
primers that hybridize to opposite strands and flank the region of interest in the target 
DNA. A repetitive series of cycles involving template dénaturation, primer annealing 
and the extension of the annealed primers by DNA polymerase results in the 
exponential accumulation of a specific fragment whose termini are defined by the 5’ 
ends of the primers.
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In this study, in order to amplify the p73 cDNA or gene fragments this method 
was applied by using different sets of primers given in table 2.1. and 2.3.
A standard 50 ul reaction set up in a 0.2 ml PCR tube with the amounts listed
below:
Primers (10 pmol/ul): 1 ul of each primer (reverse and forward)
dNTPs (10 nM): 1 ul
Buffer; 5 ul from the lOX stock
MgCl2 (25 mM); 3 ul
Template DNA: 1 ul of cDNA
Enzyme: 3 unit of Taq Polymerase enyzme
MiliQ water; adjusted to the final volume of 50 ul.
In order to amplify the desired region, a temperature profile was set to be:
Initial dénaturation: 95 °C, 3 minutes
For 30 cycles:
Dénaturation; 95 °C, 30 seconds.
Primer annealing; 60 °C, 30 seconds.
Primer Extension: 72 °C, 30 seconds.
For final extension: 72 °C, 10 minutes
Termination: 4°C
2.2.8. Agarose Gel Electrophoresis
To check the amplification status, the amplified fragments are tested with the
Agarose Gel Electrophoresis (AGE) technique. In this technique, within the linearly
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Table-2.1.: Synthetic oligonuclotide primers used for RT-PCR analysis
Name
' ' VA - A '·■·.··■■.
Sequence 5’-> 3’ ; .
Location
Strand
Position*
Size
Tin
"C
GA317 cggaattcac caccatcctg sense 850 20 63.5
TCI 60 gcgcgagttc tactgctgcg cggtgctgta antisense 1790C 30 80.5
GA313 tcctttgagg gccgcatctg sense 975 20 68.0
TCI 62 gcgcgaattc tcagtggatc tcggcctccg antisense 2012C 30 78.3
TCI 83 cgcacagttc ggcagctaca sense 1417 20 65.8
TCI 82 gtttggcaccc ccaatcctgt antisense 1617C 20 67.4
TC406 agggccccca ggtcctgacg antisense 1696C 20 72.2
TC382 tgaaggtcgg agtcaacgga tttggt sense - 26 71.4
TC383 catgtgggcc atgaggtccaccac antisense - 24 73.9
TC226 tgcagccaaa gtgaagaggg aaga sense - 24 68.5
TC227 catagcgagc agcccaaaga agaa antisense - 24 67.8
TC224 cacagcattc cttcagttta ctggagatcg sense - 30 70.2
TC225 cagcatcgat cccacttttc caagttccag antisense - 30 74.6
* Denotes the base pair positions o f primers on the p73a cDNA sequence
polymerized medium like agarose and a suitable electrolytic buffer, charged molecules 
such as DNA or RNA are oriented and migrate towards the corresponding attractive 
node when electric current is applied into the system. Since charge per unit mass is the 
same for these molecules, each DNA or RNA fragment is migrated towards the 
opposite pole with the rate proportional to its molecular mass, that is, the longer the 
fragment , the slower the migration rate, resulting the effectively separation of the 
molecules that differ in size. Moreover, by changing the concentration of the agarose, 
one can change the effective range of separation in the electrophoresis system as shown 
in the table 2.2.
39
Table 2.2.: Agarose concentration vs. effective range of separation of DNA
Effective range of separation of DNA (in kb) Amount of agarose (л\/у)
5-60 0.3
1-20 0.6
0.8-10 0.7
0.5-7 0.9
0.4-6 1.2
0.2-3 1.5
0.1-2 2.0
Generally TAE (Tris-acetic acid-EDTA) and TBE (Tris-Boric acid-EDTA) 
buffers are used as conductive media. TBE buffer is recommended for high voltage 
and short runs whereas TAE buffer is most suitable for the procedures that require low 
voltage and long run time.
In this study, TBE buffer was used as an electrolyte with the final concentration 
of IX. Agarose, which is produced as powdered form form the seaweed, was added to 
the IX TBE containing flask and is heated until all the agarose powders were 
completely dissolved as the mixture gets transparent. Heated mixture was allowed to 
cool down to approximately 60°C, then appropriate amount of ethidium bromide dye 
(10 mg/ml) was added into the heated agarose solution. After mixing and evenly 
distributing the dye in the mixture, the gel was poured into the previously-set gel 
casting system defined by the comb and the clamps. The gel was solidified and ready to 
be loaded. After the solid gel was removed from the casting apparatus, the comb was 
removed, leaving the wells in which the DNA in question was loaded. Samples were 
mixed with the loading buffer containing xylene cyanol and bromo phenol blue and 
loaded into the wells.
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A typical gel run was carried out at 80-110 V . After the run, bands 
corresponding to the expected products were visualized under the UV illluminator.
2.2.9. Isolation of genomic DNA
As stated earlier, tumor DNA samples were extracted previously by 
phenol/chloroform DNA extraction method and stored at -20 °C.
2.2.10. PCR amplification of p73 gene
The basis and the parameters of this method described in part 2.2.7. were 
also the same for the amplification of p73 exonic fragments except genomic 
DNA was used as a template. The exon-specific primers used in this study are 
outlined in table 2.3.
Table 2.3. Synthetic oligonucleotide primers of p73 DBD exons used for 
heteroduplex and radioactive SSCP analysis
■Name, ' Se'quence'5 ' 3 ’
Location
 ^Strand Position
. Tni f
GA307 ctccccgctc ttgaagaaac sense 542 20 61.1
GA322 tgtccttcgt tgaagtccct antisense 721C 20 59.5
GA323 ctgctccagc cagccacctc sense 733 20 68.1
GA324 accacgacgc tctgcctggcc antisense 814C 21 73.4
GA317 cggaattcac caccatcctg sense 850 20 63.5
GA318 actcccgcat ctccagg antisense 959C 17 59.4
GA313 tcctttgagg gccgcatctg sense 975 20 68
GA320 gcacgcttgc tggcggcccc antisense 1087C 20 78.4
2.2.11. Agarose Gel Electrophoresis
The basis of this method is explained in part 2.2.8. and no longer will be 
discussed here. In this study, amplifications were visualized in 2% agarose gel.
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2.2.12. Non-radioactive Heterodupiex Analysis
The basis of this technique depends on the fact that two complementary DNA 
strands derived from alleles that differ in sequence will include mismatched positions 
when base paired. Such double-stranded heterodupiex molecules may show altered 
migration in native gels when compared to homoduplexes of either allele. (White et 
al.,1993). With this concept, heterodupiex analysis has been applied for most of the 
mutation detection experiments so far. The method was further modified and the use of 
was replaced with ethidium bromide fluorescence to detect re-annealed 
heteroduplexes (Xing et al., 1996).
In this study, we applied this technique in order to detect possible mutations in 
the p73 DNA-binding domain.
10% Non-denaturing Polyacrylamide Gel is prepared as follows:
30% Acrylamide stock : 16.7 ml
Glycerol: 5.0 ml
lOX TBE: 5.0 ml
Agarose: 250 mg
dH20. 23.3 ml
APS: 350 ul
TEMED: 20 ul
Final Concentration: 50 ml
In an appropriate flask, the indicated amounts of lOX TBE, Glycerol, dH20 and 
agarose were added and put into microwave in order to melt the agarose. After the
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solution cooled down to 65°C, Acrylamide stock, APS and TEMED were added, mixed 
and the resulting solution was poured into previously casted apparatus.
In order to prepare the samples, equal amounts of amplified products from 
control and tumor samples were put into a 0.2 ml PCR tube. Dénaturation has carried 
out as described by Xing et al. ;
95 ° C 8 min.
90 °C
80 °C
70 °C
1 min.
1 min.
1 min.
Room Temperature
After the samples have been loaded properly, PAGE was set to run at 200 V for 
10 minutes, 180 V for 60 minutes and 140 V for 22 hours. After the removal of the gel 
from the apparatus, ethidium bromide staining was applied. Gel was put into distilled 
water containing 0.5 ug/ml ethidium bromide for 40 - 60 minutes and then visualized 
under UV light.
2.2.13. Radioactive SSCP analysis:
The basis of the SSCP technique is that; Two single-stranded DNA molecules 
from each denatured PCR product assume a three dimensional conformation which 
depends on the primary nucleotide sequence. So, a sequence change that exist on one 
or both strands may result in the mobility difference of single-stranded DNA molecules.
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In this study, 25 ul of PCR reaction was set with the following amounts:
lOX PCr buffer: 2.5 ul
dNTP(lOmM): 0.1 ul
MgCl2 (25 mM): 1.5 ul
Primer (10 pmol) forward: 1.0 ul
Primer (10 pmol) reverse: 1.0 ul
Taq DNA Pol (4u/ul): 0.5 ul
"^ P dCTP: 0.01 ul
Template DNA: 1.0 ul
ddH20: complete to 25 ul
The same temperature profile explained in section 2.2.7. was used. The amplified 
products were mixed (18ul loading buffer/2 ul PCR product) with SSCP-loading buffer 
containing 95% (v/v) formamide, 0.01% (w/v) bromophenol blue and NaOH (10 mM). 
Single-strand products were obtained by incubating them at 95 ° C for 5 minutes and 
then immediately placing them in the ice for 5 min.
Prepared samples were loaded into polyacrylamide gel that was prepared as 
follows:
lOXTBE: 5 ml
Acry^isacry.(49.5%/0.5%): 6 ml 
Glycerol: 5 ml
APS: 0.7 ml
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TEMED:
Water;
30 ul
up to 50 ml
PAGE was performed at 200V. Running time was between 6 and 8 hrs 
depending on the size of the product. After the run, the gel was dried and placed in a 
casette for autoradiography.
2.2.14. Restriction Enzyme analysis:
In order to screen for p73 mutations at residues homologous to p53 mutational 
hotspots, restriction enzyme analysis was done.
In restriction enzyme analysis (REA), known sequences are digested with 
restriction enzymes that specifically recognize and cleave the sequence. Since any base 
change in the sequence abolishes the activity of enzyme, resulting digestion pattern can 
reveal the nature of the sequence. If there is an alteration (if ATGCTA is changed to 
ATTCTA e.g.), the enzyme can not recognize the sequence and the product remains 
undigested. After the digestion products are resolved in an agarose gel, the migration 
pattern can give information about the digestion status of the product, hence the nature 
of the sequence.
Restriction enzyme analysis was performed by Kezban Unsal using Msp I and 
Hae III enzymes. It was possible to screen for possible mutations at codons 268 
(homolog of p53-248), 269 (homolog of p53-249) and 302 (homolog of p53-282) of 
p73 gene (Figure 2.1). A typical digestion reaction was prepared in a total volume of 30 
ul as follows;
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p73 gene (Figure 2.1). A typical digestion reaction was prepared in a total volume of 30 
ul as follows:
DNA template: 20 ul
1 OX RE buffer: 3 ul
Enzyme: 1 ul
dHoO: 6 ul
Resulting digestion fragments are resolved in 2.5% agarose-NuSieve agarose
Figure 2.1: Mutational hotspots that are conserved also in p73 and the 
enzymes used for the REA:
gel.
Msp I
(cfcGG)
Hae III
(ggIc c)
I-----1 I I
. CATGGGCGGCATGAACQGSSaeBiCCCATCCTCACCAT, 
. GTAGGGGGCATGAACCQESCaaSJdCCATCCTCATCATC.
/ \
p73 268 269
p53 DNA seq. 
p73 DNA seq.
Codon: (p53 248) (p53 249)
Msp I
(cfcGG)
.TCCTGGCCGCGaS hIaaAGCTGATGAGG....... P73 DNA seq.
.TCCTGGGAGAGACliiSCGCACAGAGGAAG....... P53 DNA seq.
i
Codon p73 302 
(p53 282)
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2.2.14. Direct DNA sequencing
DNA sequencing (DS) refers to the direct sequence analysis by PCR products 
without prior sub-cloning into sequencing vectors. All the methods are capable of 
detecting mutations with varying efficiencies, but none defines precisely the nature of 
the change except direct DNA sequencing. In this method, the template, which is a 
previously amplified PCR product, is simultaneously amplified and sequenced by the 
addition of dideoxy terminators to a PCR reaction. Fluorescently labeled dideoxy 
terminators with different fuorescent dye-coupled to each of the four ddNTPs, the 
sequencing product is labeled at the site of the dideoxy termination rather than at the 
sequencing primer end. The bands giving different colors and different peak values are 
analyzed by an automated sequencing machine resulting the primary DNA sequence. 
These analyses were performed by Marie Ricciardone and Hilal Ozdag. The fragments 
previously amplified were prepared for the sequencing by using ABI PRISM™ Dye 
terminator cycle sequencing core kit and 3.2 pmol of exonic forward and reverse 
primers previously shown in table 2.3.Then, samples were sequenced with the help of 
ABI PRISM™ 377 DNA sequencer.
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3-RESULTS
3.1. The expression of p73 in HCC cell lines
p73 gene, which is a newly-discovered p53 homolog, has two distinct 
alternatively spliced forms namely p73a and p73p. Former one encodes a protein 
product that is 636 amino acids long whereas the latter results from alternative splicing 
that skips exon 13 hence creates a truncated 499 amino acids-long protein. So, these 
two forms are almost identical except the last 5 residues of p73p (Kaghad et al., 1997). 
It has been reported that these two forms are expressed in all the human tissues tested 
including brain, kidney, placenta, colon, heart, liver, spleen and skeletal muscle, 
indicating a widespread but low level of expression of these forms (Kaghad et al., 
1997). In transfection experiments p73a form was found to induce p2IAVAFl gene 
transcription (Kaghad et al., 1997) and apoptosis (Just et al., 1997). Although it has also 
been shown that these two forms differ in their homotropic interaction and interaction 
with p53 in yeast two hybrid assays (Kaghad et al., 1997), there are no data so far that 
explains their mode of regulation and possible implications in cellular mechanisms. 
Kaghad and his coworkers examined the expression of these forms in neuroblastoma- 
derived and several other cell lines including HT-29 (colorectal cancer cell line) and 
MCF-7 (breast cancer cell line). The loss of both a  and P transcript was shown in SK- 
N-AS neuroblastoma cell line (Kaghad et al.,1997). At the time we began this study, 
there was no other published information about the expression pattern and the possible 
implications of these forms in normal and malignant cells. So we aimed to analyze the 
expression of these two alternatively-spliced forms in liver and HCC-derived cell lines.
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Eight different cell lines and one control cell line, HT-29 that was reported to 
express both forms (Kaghad et al., 1997), were chosen and grown under the conditions 
explained in materials and methods part.
Total RNA was extracted and tested for integrity by gel electrophoresis. 
Formaldehyde-containing 1% agarose gel was prepared and samples were run under 70 
V for 2 hours. As shown in figure 3.1., all RNA samples were good quality. There was 
no degradation.
Figure 3.1. Total RNAs as tested by Et-Br staining
6 7 8
28S
18S
Lanes: Total RNAs extracted from cell lines: 1; HT29, 2; Hep3B-TR, 3: 
Hep3B, 4; Mahlavu, 5: Chang, 6; WRL68, 7: FOCUS, 8: HepG2 and 9: PLC/PRF/5 
respectively.
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3.1.1. Establishment of a new method for combined analysis of alternatively 
spliced p73 transcripts
cDNAs corresponding to each cell line was synthesized using Promega Reverse 
transcription system with 1 ug of extracted RNAs.
In this study, in order to analyze the alternatively-spliced forms of p73, we first 
applied nested-PCR technique with the primer pairs GA317-TC162 (Exon 7 forward- 
exon 14/2 reverse) for the first round and GA313-TC160 (Exon 8 forward-exon 14/1 
reverse) for the second round of amplification. For the second round PCR, 1 ul of the 
first round product was used as a template. The resulting band pattern for three cell 
lines is shown in figure 3.2. We chose nested-PCR technique since no bands 
corresponding to p73 forms were observed in the control experiments with a single 
round PCR reaction.
In the control amplification, we observed no band for p73p form in Mahlavu 
cell line. Another observation was that the intense amplification of p73a form with 
respect to the other, probably due to the difference in the initial copy number of these 
two forms or the initial preference of the primers towards p73a form.
Figure 3.2.: Nested-PCR amplification diagram and results
p73a
Exon: 2 3 6 7 8 9 10 11 12 13 14
r ‘ round amp. GA3I7 TC162
2 round amp. GA212 TC160
Exon: 2 3 6 7 8 9 10 11 12 14
p73p
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1 2 3 4 5
p73a (835 bp)
p73p (741 bp)
1353 bp
1078 bp 
872 bp
603 bp
Lanes; 2"‘‘ round amplification results. Lane 1 is a negative control; lane 2 to 4 
are RT-PCR results using cDNAs of Mahlavu, HepG2 and Hep3B cells. Lane 5 is 
())X174/Hae III marker. The four bands seen correspond to 1353, 1078, 872 and 603 bp 
respectively.
So, in order to increase both the specificity and sensitivity of the technique, we 
established a new method to analyze these alternatively-spliced forms. Two transcript- 
specific antisense primers were designed for each p73 variants. Exon 13 is missing in 
p73|3 form, so one of the primers were selected form exon 13 sequence, being specific 
for p73a form. The other was chosen from the exon 12-14 boundary since in p73p 
transcript exon 12 is spliced with exon 14. The schematic illustration of these primers is 
shown in figure 3.3.
Figure 3.3. Amplification diagram of p73 forms.
Exon 2 3
r ‘ round amplification GAS 13 ITC162
2"‘‘ round amplification
r> TC183
TC183
\TC182
TC406
Exon 2 3  4 6 7 8 9 10 11 12 14
p73p
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In order to check the specificity of these primers, a standard PCR reaction was 
performed by using a p73a cDNA clone in pUC19 as a template. The result of this 
amplification is seen in figure 3.4.
Figure 3.4.: Specificity test of p73a and p73p-specific PCR primer
1 2  3 4
Lanes: Lane 1 is (j)X174/Hae III marker; 2 is negative control; 3 is amplification 
with p73a-specific primers (206 bp); and lane 4 is amplification with p73p- 
specific primers.
The expected sizes of p73a and p73p PCR products are respectively 206 and 
192 bp. p73a-specific PCR reaction yielded a 206 bp product from the p73a cDNA 
template. We also expected that p73p-specific primer pair does not give a 192 bp 
product because the template is p73a cDNA. As expected, p73p-specific PCR did not 
produce a 192 bp fragment. Instead, a 302 bp fragment was amplified. This fragment is 
probably a product of non-specific priming with the p73p specific primer. This is 
probably due to the fact that we used a cloned cDNA (at high levels) as a template.
Next, we tested both primer pairs using Hep3B cDNA as a template. As a 
round PCR, both forms of p73 cDNAs were amplified by using GA313 (exon 8
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forward) and TC 162 (exon 14 reverse) primers and 1 ul of Hep3B cDNA. In the 2"*^ 
round, 1 ul of the 1*‘ round product, one common forward primer (TCI 83 from exon 
11), two transcipt-specific reverse primers (TCI82 from exon 13 of p73a and TC406 
from exon 12-14 boundary of p73P) were used together.
In that manner, we were able to detect both a and p-specific PCR fragments in 
Hep3B cDNA. This was expected because this cell line express p73p transcripts (Figure
3.2.).When using both p73a and p73p-specific primers in the same test tube, both 
transcripts were detected simultaneously (Figure 3.5.).
Figure 3.5.: Multiplex amplification of p73 forms
1 2 3 4 5
p73a 
(206 bp)
p73p 
(192 bp)
200 bp
Lanes: Multiplex amplification of p73 forms. Lane 1: Negative control; lane 2: 
p73a; lane 3: p73P; lane 4: multiplex amplification of p73a and p forms in the 
same reaction; lane 5: marker (100 bp ladder).
As a next step, we included glucose-3-phosphate dehydrogenase (G3PDH) 
primers TC382 and TC383 (10 pmol for each) into the 1®^ and the 2"‘* round PCR
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reaction mixes. The amplification level of this gene was used as an internal control. The 
result was shown in figure 3.6.
Figure 3.6. Multiplex amplification of p73 forms and G3PDH
1 2  3 4
G3PDH 
^-------- (983 bp)
P73a (206 bp) 
p73p (192 bp)
Lanes; Multiplex amplification of p73 forms and G3PDH internal control. Lane 
1; 100 bp ladder; lane 2: Negative control; lane 3: 2”“' round amplification using 
HT29 cDNA as a template; and lane 4: 2'“* round amplification from Mahlavu 
cDNA as a template.
It is important to note that with this new method, with the help of G3PDH 
amplification, we were able to assess the quality control of the cDNAs and the semi- 
quantitative expression level of the p73 forms since each alternatively-spliced variant 
has its own specific primer, indicating the initial expression level of these two forms. 
So, although this new method requires two consecutive PCR amplifications, the
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resulting multiplex nature allowed us to analyze the expression of both forms in both 
qualitative and quantitative manner.
3.1.2. p73a and p73p form in HCC and liver-derived cell lines 
Then, we applied this new method in HCC and liver-derived cell lines. Figure
3.7. shows the result of the round PCR amplification.
In this picture, It is clearly seen that all the cells tested showed p73a expression, 
irrespective of their origin and the other criteria that are shown in table 3.1., indicating 
the constitutive expression of this form in these cell lines. On the other hand, p73p was 
not detected in 3 out of 8 HCC and liver-derived cell lines, namely WRL68, FOCUS 
and Mahlavu. These studies showed that the expression of p73 could be affected in
HCC.
We next tested the differentiation status of cells using two markers a-
fetoprotein and albumin. AFP and albumin are used as liver-specific markers. Precursor 
cells from foregut endoderm starts to produce AFP at about 10 days. The major 2.1 kb 
AFP mRNA is abundantly expressed in fetal liver. This expression ceases when mature 
hepatocytes are formed. Albumin expression is also seen at about the same time as AFP 
or a day later. This expression then gradually increases after birth. This gene is 
continuously expressed during the life time of hepatocytes and it is the most abundant 
mRNA expressed only in liver (Figure 3.8).
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1 2 3 4 5 6 7 8 9 10 11 12
Figure 3.7. RT-PCR results of two p73 forms.
G3PDH 
^  983 bp
p73a 206 bp
p73|3 192 bp
I.anes; Lanes 1 and 12 are 100 bp DNA size marker. Lane 2 is negative control. Lanes 
3 to 11 corresponds to amplifications from cell lines HT29, Mahlavu, FOCUS, WRL68, 
PLC/PRF/5, Chang, HepG2, Hep3B and Hep3B-TR respectively.
Figure 3.8.: AFP and albumin expression during hepatocyte development
Foregut — 
endoderm
AFP
Albumin
-> Hepatoblasts ->· Immature-----y. Hepatocytes
hepatocytes
56
In our study, two separate two-round-PCR was performed by using primer pairs 
TC226 and TC227 for a-fetoprotein and TC224 and TC225 for albumin. G3PDH 
primers (TC382 and TC383) were also included in both rounds of PCRs. The resulting 
amplifications were resolved in 2% agarose gel. The results are shown in figure 3.8.
we observed amplification of both markers in three cell lines Hep3B, Hep3B- 
TR and HepG2. Next, we studied primary tumors for possible mutations.
Figure 3.9.: Amplification of a-fetoprotein and albumin in cell lines
10 11
G3PDH 
(983 bp)
AFP 
(215 bp)
ALB 
(175 bp)
Lanes: Amplification of liver markers. Lane 1: Negative control; 2: HT29; 3: 
Chang; 4: Hep3B; 5: Hep3B-TR; 6: Mahlavu; 7: HepG2; 8: WRL68; 9: Focus; 
10; PLC/PRF/5; and 11: Marker (100 bp ladder)
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3.2. p73 gene mutation analysis in primary tumors
Due to its homology nature to p53, we next screened 25 primary HCC tumor 
samples with non-radioactive heteroduplex test and radioactive SSCP analysis for the 
DNA-binding region exons (exons 5, 6, 7, and 8) of p73 gene in which the greatest 
percentage of homology was shown in accordance with the conserved mutational 
hotspots that are frequently found to be mutated in variety of cancers. We have chosen 
non-radioactive HDA technique due to its convenient nature for the rapid screening of 
unknown mutations, although its sensitivity is reported to be around %70. By using 
HDA, we simultaneously screened the DBD-region exons for any possible alteration(s). 
At the same time, restriction enzyme analysis and direct sequencing were also 
performed in the department in order to detect any alteration pattern in the conserved 
codon 248, 249 and 282 (identical to p53 mutational hotspots codon 268, 269 and 302) 
of p73 gene.
3.2.1. PCR amplification of p73 exons
The primers, length of the PCR product and the figures showing the gel pictures 
for amplification of corresponding gene fragments are shown in table 3.1. Resulting 
fragments were resolved in 2% agarose gels.
3.2.2. Results p73 mutation analysis
In order to check the sensitivity of the non-radioactive heteroduplex analysis 
technique, a sample gel was prepared and previously identified mutations were 
analysed. The result is illustrated in figure 3.10.
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Table 3.1. Reference figures of p73 exonic amplifications
Exon: Primers: - .y ■ Product length: Reference figure:
5 GA307 (F) GA322 (R) 179 bp Figure 3.11.
6 GA323 (F) GA324 (R) 91 bp Figure 3.12.
7 GA317(F) GA318(R) 109 bp Figure 3.13.
8 GA313 (F) GA320 (R) 112 bp Figure 3.14.
Figure 3.10: 10% non-denaturing PAGE
Heteroduplexes
■*--------  Homoduplexes
(281 bp)
1 2 3 4 5 6 7 8 9
Lanes: Lanes 1, 4 and 7 is amplified from normal template; lanes 2, 5 and 8 has 
4 bp deletion; and lanes 3, 6 and 9 has G-^T transversion.
In this test gel, we were unable to detect a single base change that is G T 
transversion whereas a sample with 4 bp deletion gave a good heteroduplex pattern. Of 
course, the rate of detecting single nucleotide changes greatly depends to the nature of 
the base change, and this can increase or decrease the sensitivity of the technique.
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Samples that were amplified by PCR as described in section 2.2.12. were then 
analyzed in 10% non-denaturing polyacrylamide gels that were prepared as described in 
methods part. Gel pictures showing the heteroduplex analysis results of exons 5, 6, 7 
and 8 for 9 tumors are shown in figures 3.15 through 3.18 as an example.
Table 3.2. shows the previously identified characteristics of the tumor samples 
and the p73 mutation analysis results. These samples were collected from Mozambique 
and other parts of the South Africa where HB V infection and daily exposure to 
mycotoxins are high. It has been previously reported that in these areas, codon 249 of 
p53 gene was found to be mutated with a high frequency (rewieved by Puisieux and 
Ozturk., 1997).
In our study, interestingly, no p73 alteration was observed for four exons that 
span the conserved DNA-binding domain and the mutational hotspots of p73 gene by 
non-radioactive heteroduplex analysis. This screening test is not 100% sensitive. Its 
sensitivity is about 70%. Therefore we used an alternative technique (radioactive SSCP) 
to confirm heteroduplex screening results. A total of 28 PCR fragments obtained by 
amplification of exon 5 and 6 from 20 tumors. An example of SSCP result is shown in 
figure 3.19. There was no band shift in any of these samples tested. As described in 
materials and methods part. Restriction Enzyme Analysis (REA) and DNA sequencing 
(DS) were also performed for these samples in our department by Ph.D. students 
Kezban Unsal and Hilal Ozdag respectively. The DNA nucleotides encoding codons 
that are homologous to mutational hotspots for p53 gene, namely codons 268, 269 and 
302 (corresponding to codons 248, 249 and 282 of p53 gene) were analyzed and no
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change that abolish the restriction enzyme site was observed in REA. For DNA 
sequencing, although several samples could not be sequenced, all the other samples 
gave the sequence identical to wild-type (Table 3.2.; for sequencing data, see appendix
I).
Taken together, these studies indicated that p73 gene is not frequently mutated 
in HCC. This contrasts with high frequency of p53 mutations. However, it is important 
to emphasize that we screened tumors only for mutations at the DNA binding region 
exons of p73 gene. In addition, DNA sequence analysis did not give clear data on all 
samples. We can exclude only the presence of mutations at codon 268, 269 and 302 of 
p73 which are homologous to p53 mutational hotspots 248, 249 and 282. It is of 
particular interest that we did not detect mutation at codon 269 of p73 which is 
homologous to codon 249 of p53 which is an HCC-specific mutational hotspot. For 
other codons of exons 5, 6, 7 and 8, we can say that the probabilty of wild-type 
sequence is high. In other words, we may have missed about 30% of possible mutation 
by the techniques used here. In addition, other exons of p73 (exons 1-4 and 8-14) were 
not tested. Although the p53 gene does not display high rate of mutation outside the 
DNA binding region (exons 5-8), this may not be the case for p73.
In conclusion, our observations indicate that 3 codons of p73 (268, 269 and 302) 
which are homologous to 3 of the five p53 mutational hotspots (codons 248, 249, 282) 
do not display mutations in 25 tumors tested. In addition, mutations at exons 5, 6, 7 and 
8 of p73 appear to be rare or inexistent because a rapid mutation screening technique 
(heteroduplex analysis) failed to detect any mutations. However, p73 may display
mutations in other exons which are not tested during this study.
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Figure 3.11: PCR Amplification of p73 exon 5
179 bp 
81 bp
Lanes: Lane 1, 2, 3 and 4 were amplified from control samples; lane 5 is 
negative control; lane 6 is 81 bp exon 6 product that was used as a marker.
10
179 bp
Lanes: Lane 1 : negative control; lanes 2 through 9 are amplified from tumor 
samples T47, T15, K15T, K3T, K i l l ,  T55, T51 and T9 respectively. Lane 10 
is previously amplified exon 5 product that serves as a marker.
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1 2 3 4 5 6
Figure 3.12: PCR Amplification of p73 exon 6
81 bp
Lanes: Lane 1 is negative control; lanes 2 through 5 is exon 7 fragments 
amplified using control DNA; lane 6 is 100 bp DNA ladder used as size marker.
4 5 6 8 9 10
81 bp
Lanes: Lane 1 is negative control; Lanes 2 through 9 is exon 7 fragment 
amplified from tumor samples T15, K3T, T27, K3T, T29, T37, T55 and T13 
respectively. Lane 10 is 100 bp DNA size marker.
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Figure 3.13.: PCR Amplification of p73 exon 7
3 4
204 bp 
109 bp
Lanes: Lane 1 is negative control; lanes 2 to 6 show exon 8 fragments 
amplified using control DNA; lane 7 is previously amplified 204 bp p2l'^'^' 
promoter fragment used as a marker.
204 bp 
109 bp
Lanes: Lanes 1 through 5 correspond to amplified exon 8 fragments amplified 
from tumor samples T13, T29, T9, T37 and T15 respectively. Lane 6 is negative 
control; lane 7 is previously amplified 204 bp p21^"^' promoter fragment used 
as a marker.
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Figure 3.14.: PCR Amplification of p73 exon 8
1 2 3 4 5 6 7 8
‘ Л', i, -'Ц <·* V.
<-----  112 bp
Lanes: Lane 1 is negative control; lanes 2 to 7 are PCR products using 
control DNA as a template; lane 8 is 100 bp DNA size marker.
1 2 3 4 5 6 7
◄------112 bp
Lanes: Lane 1 is negative control; lanes 2 through 6 are PCR products from 
tumor samples T27, T29, T37, T55 and T13 respectively. Lane 7 is 100 bp 
DNA size marker.
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Figure 3.15.: Heteroduplex analysis of p73 exon 5.
1 2 3 4 5 6 7 8 9  10 11
.  •^»V . '" "  V . _ ·  ^ ^  ^1 ·  ^ ^  ,  V.« .■‘•* \
V , V , ^  »·<' 5 j: . ·'
'■"■'tf rv"·«^·· '*r ■u»*'■' ''
' / /1: ^
m 0 i  . ' ■ ^  . ^ a .  - '  ■
.^ flsIfAsssk;-·
179 bp
Lanes: Lanes 1 through 9 corresponds to fragments amplified from tumor samples 
T23, T33, T43, T29, T37, T13, T8, T39 and T41. Lane 10 is used 179 bp exon 6 
fragment used as marker.
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Figure 3.16.; Heteroduplex analysis of p73 exon 6.
1 2 3 4  5 6 7  8 9 10
4··; i , .
■ ■. ■
81 bp
Lanes: Lanes 1 through 9 corresponds to РІА samples of T43, T29, T37, T13, T23, 
T33, T8, T39 and T41. Lane 10 is 100 bp DNA size marker.
68
Figure 3.17.: Heteroduplex analysis of p73 exon 7.
1 2 3 4  5 6 7 8 9  10
109 bp
109 bp
Lanes: Lanel is 100 bp DNA size marker; Lanes 2 to 10 are HA samples of 
T37, T13, T29, T23, T33, T8, T41, T39 and T43 respectively.
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Figure 3.18.: Heteroduplex analysis of p73 exon 8.
1 2 3 6 7 8 9 10
112 bp
179 bp
112 bp
81 bp
3.2.3. Lanes: Lane 1 to 9 are HA samples of T23, T29, T37, T13, T33, T43, 
T8, T39 and T41 respectively; lane 10 is PCR products of exons 5 (179 bp) 
and 6 (81 bp).
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Figure 3.19.: Radioactive SSCP analysis of exon 5
^------ Single
^____ strands
-i------ Double
strand
Lanes: Radioactive-SSCP analysis of HCC tumors: Lanes 1 to 4 represents 
tumors T17, T31, T39 and T55.
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4-DISCUSSION
For almost 20 years after its discovery, p53 gene has become a center of 
scientific interest for its exceptional role in tumor development (reviewed in Oren M., 
1997). Its variety of functions including cell cycle arrest, apoptosis and induction of 
cell senescence in response to genotoxic stress led scientists to search for its possible 
homolog(s) but these intentions gave no positive results until Kaghad et al. had 
discovered the p73 gene which shows mono-allelic expression and considerable 
homology to p53 in both structural and functional manner (Kaghad et al., 1997). p73, 
when over-expressed, was observed to induce p21AVAFl transcription and apoptosis 
(Kaghad et al., 1997; lost et al., 1997). Moreover, all the hotspots whose alterations 
result in the altered or abolished response of p53 were found to be conserved in the p73 
gene. It has also been reported by Kaghad et al. that unlike p73a form, p73p form 
shows high binding affinity to p53. It has been suggested that disruption of normal p53 
function may result in compensatory or deleterious up-regulation of p73 (Kaghad et al., 
1997). These results, taken together, increase the possible tumor suppressor role of p73
gene.
In this study, our aim was to test whether p73 gene was altered in hepatocellular
carcinoma. So we decided to study both the expression and the structure of p73 gene for 
possible abnormalities. We first analyzed the expression pattern of p73 forms in HCC 
and liver-derived cell lines. A sensitive two-step RT-PCR method was developed for
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simultaneous analysis of p73a and p73p transcripts. In order to avoid the mis­
interpretations and sampling errors, with the help of nested-PCR technique and 
transcript-specific primers, two p73 forms, together with the internal control G3PDH 
were amplified. In the round PCR, in addition to G3PDH primer pairs, a set of p73 
primers that are flanking exon 9 and exon 14 were used to amplify both forms. In the 
second round PCR, a standard reaction was set with 5 different primers (one p73 
forward primer, one p73a and one p73P-specific reverse primer and two G3PDH 
primers) and three transcripts (p73a, p73p and G3PDH) were co-amplified in the same 
reaction mixture by using 1 ul of the first PCR products. This method, owing to its 
multiplex nature and specificity, is very convenient for simultaneous analysis of a  and 
P forms. The set of specific primers for p73a and p73p allowed us to avoid false 
positive or false negative results due to preferential amplifications. The addition of an 
internal control (G3PDH) to PCR reaction allowed to demonstrate that equal amounts 
of cDNA products were used in different experiments.
We next analyzed p73 expression pattern with this newly-established technique. 
p73a expression was found to be constitutive, since it was found to be expressed in all 
the cell lines examined. However, the loss of expression of p73p form was detected in 
3/8 of the cell lines. Known characteristics of the cell lines together with the p73 status 
was shown in table 4.1. The p73p was not detectable in 2 HCC cell lines (Focus and 
Mahlavu) and one cell line derived form embryonic liver (WRL68). Thus, there was no 
specific loss due to malignancy of the primary tissue. There was also no correlation 
between p53 status and the absence of p73p. Similarly, there was no apparent relation
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to find was the differentiation status of the cell lines. The published data on the 
differentiation status of these cells indicated that 5 cell lines (Chang, PLC/'PRF/5, 
Hep3B, Hep3B-TR and HepG2) were differentiated, and 3 (WRL68, Focus and 
Mahlavu) were undifferentiated.
The differentiation status of these cell lines was checked by using two markers 
(albumin and a-fetoprotein) transcripts by RT-PCR. Amplification of both markers 
were detected in 3/5 of differentiated (namely Hep3B, Hep3B-TR and HepG2) but not 
in 3 undifferentiated cell lines.
In contrast to these observations, we failed to detect p73 gene mutations at the 
DNA binding region (exons 5-8) in 25 primary tumors. Thus, p73 gene, does not 
appear to be mutated in HCC. In the light of recent studies on the status of p73 in lung, 
prostate and colon cancers, this is not unexpected (Nomoto et al., 1998; Takahashi et 
al., 1998; Mai et al., 1998; Sunahara et al., 1998). Indeed, It becomes now clear that 
p73 gene is not frequently mutated in human cancers. Thus, unlike p53, the p73 gene 
appears not to be a target for mutations causing malignant transformation of cells.
However, our observation indicate that the expression of p73 gene is modulated 
according to the differentiation status of hepatocyte-derived cell lines. The loss of p73^ 
in undifferentiated cell lines can be a cause or a result of the loss of cellular 
differentiation.
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Table 4.1.: Data collected from previous reports and p73 expression status 
of cell lines
p73a and P can work on different sets of genes. As p is lost in undifferentiated cells, it 
could act specifically for the induction of expression of liver-specific genes.
Our studies started almost a year ago, just after the discovery of p73. During the 
last months more data about p73 and other p53-homologue genes became available. 
Similar to our observations, the lack of p73 mutations was reported for different 
cancers, including lung, prostate and colon carcinomas (Nomoto et al., 1998; Takahashi 
et al., 1998; Mai et al., 1998; Sunahara et al., 1998). Thus, it appears that, unlike p53, 
p73 gene is not mutated in cancer. The lack of tumors in p73 knock-out mice also favor 
the hypothesis that p73 may not a classical tumor suppressor gene (Kaelin GW., 1998). 
However, these observations do not rule out the possibility of aberration other than 
mutation of p73 in cancer. In this regard, the expression pattern of p73p may indicate a 
subtle role of alternative splicing of p73 in tumor development and/or dedifferentiation. 
Tumor progression is often accompanied by the loss of differentiation in cancer cells. 
Alternatively p73 and other p53 like genes may play a direct role in differentiation 
and/or in specific cell types. For example, specific expression of p73 in neural type
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cells has been reported (Osada et al., 1998). The data about two other p53-like genes, 
namely p51 (human homolog of ket gene in rat) and p40 is very scanty (Osada et al., 
1998; Trink et al., 1998). The only noticeable data is the presence of p51 mutations in 
some rare cases of epidermal cancers (Osada et al., 1998). It is possible that p53 is a 
house-keeping gene present in all cells while p53-like genes have more specific 
functions. Alternatively, p53-like genes may have redundant functions, explaining why 
they are not a target for mutation. Indeed, there are several examples of gene families in 
which only one gene is mutated in cancer, but not others. For example, among Rb- 
family genes (pi 10, pl30 and pl07) onlyRbl is mutated. Similarly, among cyclin- 
dependent kinase inhibitors (pl5, pl6, p21, p27, p57), only pl6 is known to be 
frequently mutated in cancers (Kaelin GW., 1998). The lack of mutation does not 
necessarily indicate that such genes are not important in maintaining normal phenotype.
The era of p53-like genes is just starting. The future will tell how they are 
involved in normal cellular function.
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5-PERSPECTIVES
In this study, we found that in three out of eight cell lines, there was a loss of 
expression of p73|3 form in correlation with their undifferentiated status. Up to now, 
many inactivation pathways such as mutational inactivation, change in the half-life in 
both the protein and mRNA level, promoter-specific méthylation as well as regulation 
pathways have been described or proposed, resulting in an aberrant phenotype 
(reviewed by Liggett WH. and Sidransky D., 1998; Guinn BA. and Mills KI., 1997; 
Ko LJ. And Prives C., 1996). Differential expression of p73p may also be due to other 
unknown mechanism. For example, the proliferation state of cell lines may correlate 
with cell cycle phase-specific expression of p73p.
Our future analysis should be concentrated on a more careful analysis of p73(3 
transcripts in cell lines. Cells could be synchronized in cell cycle and the expression of 
p73p could be tested at selected phases such as G,, S and G2/M.
If our observation with p73p are confirmed with additional studies. It will be 
interesting to compare specific functions of p73a and p73j3 transcripts. As the 
expression of p73p appears to correlate with cellular differentiation, it may be a 
transcription factor acting on tissue-specific gene expression. With regard to our 
experimental model, we plan to construct p73p expression vector and then transfect 
hepatoma cell lines. Such transfected cell lines will be tested to know whether p73p 
expression can induce the expression of liver-specific genes such as albumin and a -
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fetoprotein. The differentiation is often accompanied by an exit from cell cycle. Then 
the effects of p73p on cellular proliferation should also be studied.
Additionally, since we analyzed the expression of p73 only in cell lines, this 
expression analysis should be performed also in primary tumor samples as well as their 
normal counterparts. In that manner, p73 expression should also be analyzed with larger 
sampling size, probably showing the relevance of this change in tumor development.
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7-APPENDIX:
DNA-Sequencing results of p73 exons (exons 5, 6, 7, 8) and the homologues of p53
mutational hotspots:
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